Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06543108

Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gastric Cancer Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 18 years old;
  • Diagnosed as a patient with gastric cancer;
  • Receive FAPI PET/CT and FDG PET/CT imaging within one week;
  • Perform serum tumor marker testing one week before and after scanning

Exclusion criteria

  • History of other malignant tumors;
  • Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;
  • Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;
  • Patients with unorganized pathology or incomplete clinical data

Treatment and study plan

The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer

Diagnostic Test

The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer

Primary outcomes

  1. 18F-FAPI-04 PET imaging diagnosis of gastric cancer detection rate

    Time frame: 2 years

    Exploring the feasibility of using targeted fibroblast activation protein (FAP) PET/CT imaging for gastric cancer; Compare the advantages and disadvantages of 18F-FAPI-04 and 18F-FDG in gastric cancer imaging, explore the clinical application value of 18F-FAPI-04 PET/CT in gastric cancer imaging, and construct a molecular imaging diagnostic model for gastric cancer

Secondary outcomes

  1. Detection rate of peritoneal metastasis in gastric cancer

    Time frame: 2 years

    Comparison of the diagnostic value of 18F-FAPI-04 PET/CT and PET/MR for peritoneal metastasis of gastric cancer, and construction of a molecular imaging diagnostic model for peritoneal metastasis of gastric cancer

Study contacts

Contact information is provided by the study sponsor or research team.

Hui Ye

CONTACT

[email protected]

86-13755117105

Sponsors and collaborators

Lead sponsor

Hunan Cancer Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
Aug 7, 2024
Registry last updated
Aug 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.